

Neptune Technologies & Bioresources Inc.  
Form 6-K  
April 14, 2010

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 6-K**

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of: April 2010

Commission File Number: 001-33526

**NEPTUNE TECHNOLOGIES & BIORESOURCES INC.**

(Name of Registrant)

**225 Promende du Centropolis**

**Suite 200**

**Laval, Québec**

**Canada H7T 0B3**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F [ ]

Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]

Edgar Filing: Neptune Technologies & Bioresources Inc. - Form 6-K

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes [ ]

No [X]

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**NEPTUNE TECHNOLOGIES & BIORESOURCES INC.**

Date: April 14, 2010

By:	/s/ Henri Harland
Name:	Henri Harland
Title:	President and Chief Executive Officer

**EXHIBIT INDEX**

Exhibit      Description of Exhibit

99.1      Acasti Pharma Inc. to showcase at the Cambridge Healthtech Institute and the BioPharmaceutical Strategy Series

---